Advertisement

Successfully Integrating the FDA Regulations into Your Practice

  • Wendy D. LatashEmail author
Chapter

Abstract

The fertility field has had its challenges with regard to state and federal regulations over the past 20 years. In 2005, ART programs were faced with a new regulatory challenge - the Food and Drug Administration. The ruling entitled “21 CFR Part 1271 Human Cells, Tissues, and Cellular and Tissue-Based Products” regulates non-vascularized human tissues including reproductive tissues and touches on donor and non-donor tissues affecting the clinical, as well as the laboratory areas of an ART program. This chapter examines the history of ART regulation, defines the scope of what is regulated for ART programs, and describes the most important aspects of the ruling that medical and laboratory directors need to know for compliance. In addition, practical “field-tested” information from a fertility perspective is given on how to develop and maintain a compliance program specifically focused on dealing with the 21 CFR Part 1271 ruling. Finally, case examples from real donor situations are described in order to test the reader’s knowledge and comprehension of the regulations as applied to an ART program.

Keywords

Fertility Reproductive tissue FDA regulations 21 CFR Part 1271 Donor eligibility determination Current Good Tissue Practice Relevant communicable disease Human Cells Tissues and Cellular and Tissue Based Products (HCT/Ps) 

References

  1. 1.
    Henkel J (1994) Safeguarding human tissue transplants. FDA Consum 28(7):9-13PubMedGoogle Scholar
  2. 2.
    U.S. Department of Health and Human Services; Food and Drug Administration (2003) 21 CFR part 1271: human cells, tissues, and cellular and tissue-based products; establishment registration and listing; final rule; delay of effective date. Fed Regist 68(13):2689-2691Google Scholar
  3. 3.
    U.S. Department of Health and Human Services; Food and Drug Administration (2004) 21 CFR part 1271: human cells, tissues, and cellular and tissue-based products; establishment registration and listing; interim final rule; opportunity for public comment. Fed Regist 69(17):3823-3826Google Scholar
  4. 4.
    U.S. Department of Health and Human Services; Food and Drug Administration (2001) 21 CFR parts 207, 807, and 1271: human cells, tissues, and cellular and tissue-based products; establishment registration and listing; final rule. Fed Regist 66(13):5447-5469Google Scholar
  5. 5.
    U.S. Department of Health and Human Services; Food and Drug Administration (2004) 21 CFR part 1271: human cells, tissues, and cellular and tissue-based products; establishment registration and listing; correction. Fed Regist 69(23):5272Google Scholar
  6. 6.
    U.S. Department of Health and Human Services; Food and Drug Administration (2008) 21 CFR part 1271: human cells, tissues, and cellular and tissue-based products; CFR correction to 1271.22. Fed Regist 73(13):3387Google Scholar
  7. 7.
    U.S. Department of Health and Human Services; Food and Drug Administration (2005) 21 CFR part 1271: human cells, tissues, and cellular and tissue-based products; donor screening and testing, and related labeling; interim final rule; opportunity for public comment. Fed Regist 70(100):29949-29952Google Scholar
  8. 8.
    U.S. Department of Health and Human Services; Food and Drug Administration (2006) 21 CFR part 1271: eligibility determination for donors of human cells, tissue, and cellular and tissue-based products; correction. Fed Regist 71(57):14798Google Scholar
  9. 9.
    U.S. Department of Health and Human Services; Food and Drug Administration (2004) 21 CFR parts 210, 211, 820, and 1271: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products; final rule and notice. Fed Regist 69(101):29786-29834Google Scholar
  10. 10.
    U.S. Department of Health and Human Services; Food and Drug Administration (2004) 21 CFR parts 16, 1270, and 1271: current good tissue practice for human cell, tissue, and cellular and tissue-based product establishments; inspection and enforcement; final rule. Fed Regist 69(226):68612-68688Google Scholar
  11. 11.
    U.S. Department of Health and Human Services; Food and Drug Administration (2007) 21 CFR part 1271: human cells, tissues, and cellular and tissue-based products; donor screening and testing, and related labeling; final rule. Fed Regist 72(117):33667-33669Google Scholar
  12. 12.
    Department of Health and Human Services (1992) Medicare, Medicaid and CLIA programs; regulations implementing the Clinical Laboratory Improvement Amendments of 1988 (CLIA) - HCFA. Final rule with comment period. Fed Regist 57(40):7002-7186Google Scholar
  13. 13.
    Department of Health and Human Services (1993) Medicare, Medicaid and CLIA programs; regulations implementing the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and Clinical Laboratory Improvement Act Program fee collection - HCFA. Final rule with comment period. Fed Regist 58(11):5215-5237Google Scholar
  14. 14.
    Department of Health and Human Services; Centers for Disease Control and Prevention (1999) Implementation of the fertility clinic success rate and certification act of 1992 - a model program for the certification of embryo laboratories; notice. Fed Regist 64(139):39374-39392Google Scholar
  15. 15.
    Critser J (1998) Current status of semen banking in the USA. Hum Reprod 13(Suppl. 2):55-67 Discussion 68-9PubMedGoogle Scholar
  16. 16.
    U.S. Department of Health and Human Services; Food and Drug Administration; Center for Biologics Evaluation and Research (2007) Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps).Google Scholar
  17. 17.
    U.S. Department of Health and Human Services; Food and Drug Administration; Center for Biologics Evaluation and Research (2007) Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps). 14-21Google Scholar
  18. 18.
    U.S. Department of Health and Human Services; Food and Drug Administration; Center for Biologics Evaluation and Research (2007) Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps). 24-5Google Scholar
  19. 19.
    U.S. Department of Health and Human Services; Food and Drug Administration; Center for Biologics Evaluation and Research (2007) Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps). 21-4Google Scholar
  20. 20.
    U.S. Department of Health and Human Services; Food and Drug Administration; Center for Biologics Evaluation and Research (2007) Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps). 23Google Scholar
  21. 21.
    U.S. Department of Health and Human Services; Food and Drug Administration; Center for Biologics Evaluation and Research (2007) Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps). 13Google Scholar
  22. 22.
    U.S. Department of Health and Human Services; Food and Drug Administration; Center for Biologics Evaluation and Research (2007) Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps). 31-7Google Scholar
  23. 23.
    U.S. Department of Health and Human Services; Food and Drug Administration; Center for Biologics Evaluation and Research (2007) Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps). 33-4Google Scholar
  24. 24.
    U.S. Department of Health and Human Services; Food and Drug Administration; Center for Biologics Evaluation and Research (2007) Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps). 37-8Google Scholar
  25. 25.
    U.S. Department of Health and Human Services; Food and Drug Administration; Center for Biologics Evaluation and Research (2006) Guidance for industry: compliance with 21 CFR Part 1271.150(c)(1) - manufacturing arrangements.Google Scholar
  26. 26.
    U.S. Department of Health and Human Services; Food and Drug Administration; Center for Biologics Evaluation and Research (2007) Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps). 28-31Google Scholar
  27. 27.
    U.S. Department of Health and Human Services; Food and Drug Administration; Center for Biologics Evaluation and Research (2007) Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps). 58-61Google Scholar
  28. 28.
    U.S. Department of Health and Human Services; Food and Drug Administration; Center for Biologics Evaluation and Research (2007) Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps). 40-2Google Scholar
  29. 29.
    U.S. Department of Health and Human Services; Food and Drug Administration; Center for Biologics Evaluation and Research (2007) Guidance for industry: certain human cells, tissues, and cellular and tissue-based products (HCT/Ps) recovered from donors who were tested for communicable diseases using pooled specimens or diagnostic tests.Google Scholar
  30. 30.
    U.S. Department of Health and Human Services; Food and Drug Administration; Center for Biologics Evaluation and Research (2007) Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps). 7Google Scholar
  31. 31.
    U.S. Department of Health and Human Services; Food and Drug Administration; Center for Biologics Evaluation and Research (2007) Guidance for industry: regulation of human cells, tissues, and cellular and tissue-based products (HCT/Ps); small entity compliance guide. 11Google Scholar
  32. 32.
    Malarkey M. HCT/P Compliance update. 2008 Jan 10 [cited 2008 Feb 25]. Available from: http://www.fda.gov/cber/summaries/hctp010808mm.pdf
  33. 33.
    Wells M FDA update: relevant to reproductive establishments. 2007 Sep 17 [cited 2008 Feb 29]. Available from: http://www.fda.gov/cber/tissue/aatb091707mw.pdf
  34. 34.
    U.S. Department of Health and Human Services; Food and Drug Administration; Center for Biologics Evaluation and Research (2007) Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps). 41Google Scholar
  35. 35.
    U.S. Department of Health and Human Services; Food and Drug Administration; Center for Biologics Evaluation and Research (2007) Guidance for industry: regulation of human cells, tissues, and cellular and tissue-based products (HCT/Ps); small entity compliance guide.Google Scholar
  36. 36.
    U.S. Department of Health and Human Services; Food and Drug Administration; Center for Biologics Evaluation and Research (2007) Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps). 19Google Scholar
  37. 37.
    U.S. Department of Health and Human Services; Food and Drug Administration; Center for Biologics Evaluation and Research (2007) Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps). 31Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Jade Tree Solutions, LLCNorthbrookUSA

Personalised recommendations